Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.
Tobias J, Högler S, Raigel M, Lin DS, Chao Y, Kenner L, Garner-Spitzer E, Yavrom S, Ede NJ, Zielinski CC, Kundi M, Wiedermann U. Tobias J, et al. Among authors: zielinski cc. Int J Mol Sci. 2023 Dec 24;25(1):287. doi: 10.3390/ijms25010287. Int J Mol Sci. 2023. PMID: 38203458 Free PMC article.
9th Immunotherapy of Cancer conference (ITOC): A meeting report.
Dalloul I, Strzalkowski TJC, von Bergwelt-Baildon M, Nüssler V, Zielinski C, Kobold S. Dalloul I, et al. Hum Vaccin Immunother. 2022 Dec 30;18(7):2159706. doi: 10.1080/21645515.2022.2159706. Epub 2022 Dec 28. Hum Vaccin Immunother. 2022. PMID: 36576266 Free PMC article.
Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON).
Tobias J, Maglakelidze M, Andrić Z, Ryspayeva D, Bulat I, Nikolić I, Petrović Z, Chawla T, Nagarkar R, Garner-Spitzer E, Zielinski CC, Chong LMO, Nixon B, Ede NJ, Yavrom S, Kundi M, Wiedermann U. Tobias J, et al. Among authors: zielinski cc. Clin Cancer Res. 2024 Sep 13;30(18):4044-4054. doi: 10.1158/1078-0432.CCR-24-0742. Clin Cancer Res. 2024. PMID: 39028916 Free PMC article. Clinical Trial.
Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.
Wagner A, Garner-Spitzer E, Auer C, Gattinger P, Zwazl I, Platzer R, Orola-Taus M, Pichler P, Amman F, Bergthaler A, Huppa JB, Stockinger H, Zielinski CC, Valenta R, Kundi M, Wiedermann U. Wagner A, et al. Among authors: zielinski cc. Vaccines (Basel). 2024 May 9;12(5):518. doi: 10.3390/vaccines12050518. Vaccines (Basel). 2024. PMID: 38793769 Free PMC article.
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.
Kiesewetter B, Dafni U, de Vries EGE, Barriuso J, Curigliano G, González-Calle V, Galotti M, Gyawali B, Huntly BJP, Jäger U, Latino NJ, Malcovati L, Oosting SF, Ossenkoppele G, Piccart M, Raderer M, Scarfò L, Trapani D, Zielinski CC, Wester R, Zygoura P, Macintyre E, Cherny NI; ESMO-MCBS Working Group and Extended Working Group. Kiesewetter B, et al. Among authors: zielinski cc. Ann Oncol. 2023 Sep;34(9):734-771. doi: 10.1016/j.annonc.2023.06.002. Epub 2023 Jun 19. Ann Oncol. 2023. PMID: 37343663 Free article.
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJ. Subbiah V, et al. Among authors: zielinski cc. Nat Med. 2023 May;29(5):1103-1112. doi: 10.1038/s41591-023-02321-8. Epub 2023 Apr 14. Nat Med. 2023. PMID: 37059834 Free PMC article. Clinical Trial.
355 results